Veradermics, Incorporated MANE · Stock Open Veradermics, Incorporated in new tab
Analyst price targets
Recent rating changes, newest first
Veradermics, Incorporated Analysis (MANE)
Is Veradermics, Incorporated a good investment? Veradermics, Incorporated (MANE) is currently trading at 136.70 USD. Market analysts have a consensus price target of 170.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Veradermics, Incorporated is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is -2.64.
Investor FAQ
Does Veradermics, Incorporated pay a dividend?
No, it does not currently pay a dividend.
What asset class is Veradermics, Incorporated?
Veradermics, Incorporated is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -4.24.
Company Profile
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Community Discussion